keyword
MENU ▼
Read by QxMD icon Read
search

Kybella

keyword
https://www.readbyqxmd.com/read/27787270/prevention-and-management-of-injection-related-adverse-effects-in-facial-aesthetics-considerations-for-atx-101-deoxycholic-acid-injection-treatment
#1
Steven Fagien, Patricia McChesney, Meenakshi Subramanian, Derek H Jones
ATX-101 (deoxycholic acid injection; Kythera Biopharmaceuticals, Inc. [an affiliate of Allergan plc, Dublin, Ireland]) was approved in 2015 in the United States (Kybella) and Canada (Belkyra) for submental fat reduction. As expected, injection-site reactions such as pain, swelling, and bruising, which were mostly mild or moderate and transient, were common adverse events (AEs) reported in clinical trials. An exploratory Phase 3b study investigating interventions for management of injection-site AEs associated with ATX-101 treatment was recently completed...
November 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27787269/management-of-patient-experience-with-atx-101-deoxycholic-acid-injection-for-reduction-of-submental-fat
#2
Jeffrey S Dover, Jeffrey M Kenkel, Alastair Carruthers, Paul F Lizzul, Todd M Gross, Meenakshi Subramanian, Frederick C Beddingfield
BACKGROUND: ATX-101 (deoxycholic acid injection; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was recently approved for submental fat (SMF) reduction in the United States (Kybella) and Canada (Belkyra). The pivotal trials supporting these approvals revealed that ATX-101 is associated with common injection-site treatment reactions consistent with its mechanism of action and administration procedure. OBJECTIVE: The purpose of this study was to evaluate 4 patient experience management paradigms targeting the common injection-site adverse events of pain, swelling/edema, and bruising after a single treatment session with ATX-101...
November 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27787268/anatomy-of-the-cervicomental-region-insights-from-an-anatomy-laboratory-and-roundtable-discussion
#3
Jeffrey M Kenkel, Derek H Jones, Steven Fagien, Dee Anna Glaser, Gary D Monheit, Karen Stauffer, Jonathan M Sykes
In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-in-class injectable drug for reduction of submental fat. Use of a pharmacologic/injectable therapy within the submental region requires a thorough understanding of cervicomental anatomy to ensure proper injection technique and safe administration. To this end, an anatomy laboratory was conducted to review key external landmarks and important internal anatomic structures that characterize the lower face and anterior neck...
November 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27787267/proper-technique-for-administration-of-atx-101-deoxycholic-acid-injection-insights-from-an-injection-practicum-and-roundtable-discussion
#4
Derek H Jones, Jeffrey M Kenkel, Steven Fagien, Dee Anna Glaser, Gary D Monheit, Karen Stauffer, Jonathan M Sykes
ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas Southwestern Medical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area...
November 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27787266/overview-of-atx-101-deoxycholic-acid-injection-a-nonsurgical-approach-for-reduction-of-submental-fat
#5
Steven H Dayan, Shannon Humphrey, Derek H Jones, Paul F Lizzul, Todd M Gross, Karen Stauffer, Frederick C Beddingfield
In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-in-class injectable drug for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat. ATX-101 has been evaluated in a clinical development program that included 18 Phase 1 to 3 studies supporting the current indication. Since 2007, the toxicity and safety profiles of ATX-101 have been characterized in numerous preclinical studies, its pharmacokinetics, pharmacodynamics, and optimal treatment paradigm have been defined in multiple Phase 1 and 2 studies, and its efficacy and clinical safety have been confirmed in 4 large Phase 3 trials (2 conducted in Europe and 2 in the United States and Canada [REFINE-1 and REFINE-2])...
November 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27785706/deoxycholic-acid-a-review-in-submental-fat-contouring
#6
Emma D Deeks
Deoxycholic acid is a secondary bile acid involved in dietary fat emulsification/solubilization that causes adipocyte lysis when injected into subcutaneous fat tissue. A 10 mg/mL injectable solution of synthetic deoxycholic acid (Kybella™; Belkyra™) is indicated in various countries, including the USA and several within Europe/the EU, to improve the appearance of moderate to severe convexity or fullness associated with submental fat (SMF) in adults, where it is currently the only approved treatment for fat below the chin...
December 2016: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/27603325/sodium-deoxycholate-for-submental-contouring
#7
S Humphrey, K Beleznay, J D A Beleznay
The chin and jaw line are integral parts of an individual's aesthetic profile, and the presence of submental fat detracts from this and can lead to displeasure with one's facial appearance. While liposuction and cosmetic surgery are regarded as the gold standard in treating submental fat, surgical intervention is not appealing to all patients and has potential surgical complications including longer recovery, and contour irregularities. Despite ample advances in aesthetic medicine to enhance the appearance of the face, very little is available in non-invasive options to reduce submental fat that has been supported by robust evidence...
September 2016: Skin Therapy Letter
https://www.readbyqxmd.com/read/26682336/additional-thoughts-on-the-new-treatment-kybella
#8
Joel L Cohen, David L K Chen, Jeremy B Green, John H Joseph
With the recent approval of Kythera Biopharmaceuticals (Westlake Village, California) submental fat injectable treatment Kybella, there comes a lot of excitement-but, also a bit of concern. The idea of having a nonsurgical, nonliposuction treatment for people who have a double chin is certainly exciting. The hope has been that this new treatment will provide opportunities for the many people out there who are focused on the appearance of their submental fullness to have access to a safe. affordable, and reliable treatment...
September 2015: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/26633685/deoxycholic-acid-kybella-for-double-chin
#9
(no author information available yet)
No abstract text is available yet for this article.
December 7, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/26185402/pharmaceutical-approval-update
#10
Kunj Gohil
Deoxycholic acid (Kybella) for submental fat; codeine polistirex/chlorpheniramine polistirex extended-release (Tuzistra XR) for coughs, allergies, and colds; ramucirumab (Cyramza) for colorectal cancer; and fluticasone furoate/vilanterol (Breo Ellipta) for asthma.
July 2015: P & T: a Peer-reviewed Journal for Formulary Management
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"